Recombination Monophosphoryl Lipid A-Derived Vacosome for the Development of Preventive Cancer Vaccines

Ruoyu Cheng; Flavia Fontana; Junyuan Xiao; Zehua Liu; Patricia Figueiredo; Mohammad-Ali Shahbazi; Shiqi Wang; Jing Jin; Giulia Torrieri; Jouni Tapio Hirvonen; Hongbo Zhang; Tongtong Chen Chen; Wenguo Cui; Yong Lu; Hélder A. Santos

doi:10.1021/acsami.0c15057

Recombination Monophosphoryl Lipid A-Derived Vacosome for the Development of Preventive Cancer Vaccines

Ruoyu Cheng, Flavia Fontana, Junyuan Xiao, Zehua Liu, Patricia Figueiredo, Mohammad-Ali Shahbazi, Shiqi Wang, Jing Jin, Giulia Torrieri, Jouni Tapio Hirvonen, Hongbo Zhang, Tongtong Chen Chen, Wenguo Cui, Yong Lu, Hélder A. Santos

Research output: Contribution to journal › Article › Scientific › peer-review

8 Citations (Scopus)

5 Downloads (Pure)

Abstract

Recently, there has been an increasing interest for utilizing the host immune system to fight against cancer. Moreover, cancer vaccines, which can stimulate the host immune system to respond to cancer in the long term, are being investigated as a promising approach to induce tumor-specific immunity. In this work, we prepared an effective cancer vaccine (denoted as "vacosome") by reconstructing the cancer cell membrane, monophosphoryl lipid A as a toll-like receptor 4 agonist, and egg phosphatidylcholine. The vacosome triggered and enhanced bone marrow dendritic cell maturation as well as stimulated the antitumor response against breast cancer 4T1 cells in vitro. Furthermore, an immune memory was established in BALB/c mice after three-time preimmunization with the vacosome. After that, the immunized mice showed inhibited tumor growth and prolonged survival period (longer than 50 days). Overall, our results demonstrate that the vacosome can be a potential candidate for clinical translation as a cancer vaccine.

Original language	English
Pages (from-to)	44554-44562
Number of pages	9
Journal	ACS Applied Materials and Interfaces
Volume	12
Issue number	40
DOIs	https://doi.org/10.1021/acsami.0c15057
Publication status	Published - 7 Oct 2020
MoE publication type	A1 Journal article-refereed

Access to Document

10.1021/acsami.0c15057Licence: CC BY

Cheng et al., 2020 ACS AMIAccepted author manuscript, 1.2 MBLicence: Publisher rights policy

https://urn.fi/URN:NBN:fi-fe202201147834

Cite this

Cheng, R., Fontana, F., Xiao, J., Liu, Z., Figueiredo, P., Shahbazi, M-A., Wang, S., Jin, J., Torrieri, G., Hirvonen, J. T., Zhang, H., Chen, T. C., Cui, W., Lu, Y., & Santos, H. A. (2020). Recombination Monophosphoryl Lipid A-Derived Vacosome for the Development of Preventive Cancer Vaccines. ACS Applied Materials and Interfaces, 12(40), 44554-44562. https://doi.org/10.1021/acsami.0c15057

@article{4b00fa458f7f46599b745b3ab1cd0873,

title = "Recombination Monophosphoryl Lipid A-Derived Vacosome for the Development of Preventive Cancer Vaccines",

abstract = "Recently, there has been an increasing interest for utilizing the host immune system to fight against cancer. Moreover, cancer vaccines, which can stimulate the host immune system to respond to cancer in the long term, are being investigated as a promising approach to induce tumor-specific immunity. In this work, we prepared an effective cancer vaccine (denoted as {"}vacosome{"}) by reconstructing the cancer cell membrane, monophosphoryl lipid A as a toll-like receptor 4 agonist, and egg phosphatidylcholine. The vacosome triggered and enhanced bone marrow dendritic cell maturation as well as stimulated the antitumor response against breast cancer 4T1 cells in vitro. Furthermore, an immune memory was established in BALB/c mice after three-time preimmunization with the vacosome. After that, the immunized mice showed inhibited tumor growth and prolonged survival period (longer than 50 days). Overall, our results demonstrate that the vacosome can be a potential candidate for clinical translation as a cancer vaccine.",

author = "Ruoyu Cheng and Flavia Fontana and Junyuan Xiao and Zehua Liu and Patricia Figueiredo and Mohammad-Ali Shahbazi and Shiqi Wang and Jing Jin and Giulia Torrieri and Hirvonen, {Jouni Tapio} and Hongbo Zhang and Chen, {Tongtong Chen} and Wenguo Cui and Yong Lu and Santos, {H{\'e}lder A.}",

year = "2020",

month = oct,

day = "7",

doi = "10.1021/acsami.0c15057",

language = "English",

volume = "12",

pages = "44554--44562",

journal = "ACS Applied Materials and Interfaces",

issn = "1944-8244",

publisher = "American Chemical Society",

number = "40",

}

Cheng, R, Fontana, F, Xiao, J, Liu, Z, Figueiredo, P, Shahbazi, M-A, Wang, S, Jin, J, Torrieri, G, Hirvonen, JT, Zhang, H, Chen, TC, Cui, W, Lu, Y & Santos, HA 2020, 'Recombination Monophosphoryl Lipid A-Derived Vacosome for the Development of Preventive Cancer Vaccines', ACS Applied Materials and Interfaces, vol. 12, no. 40, pp. 44554-44562. https://doi.org/10.1021/acsami.0c15057

TY - JOUR

T1 - Recombination Monophosphoryl Lipid A-Derived Vacosome for the Development of Preventive Cancer Vaccines

AU - Cheng, Ruoyu

AU - Fontana, Flavia

AU - Xiao, Junyuan

AU - Liu, Zehua

AU - Figueiredo, Patricia

AU - Shahbazi, Mohammad-Ali

AU - Wang, Shiqi

AU - Jin, Jing

AU - Torrieri, Giulia

AU - Hirvonen, Jouni Tapio

AU - Zhang, Hongbo

AU - Chen, Tongtong Chen

AU - Cui, Wenguo

AU - Lu, Yong

AU - Santos, Hélder A.

PY - 2020/10/7

Y1 - 2020/10/7

N2 - Recently, there has been an increasing interest for utilizing the host immune system to fight against cancer. Moreover, cancer vaccines, which can stimulate the host immune system to respond to cancer in the long term, are being investigated as a promising approach to induce tumor-specific immunity. In this work, we prepared an effective cancer vaccine (denoted as "vacosome") by reconstructing the cancer cell membrane, monophosphoryl lipid A as a toll-like receptor 4 agonist, and egg phosphatidylcholine. The vacosome triggered and enhanced bone marrow dendritic cell maturation as well as stimulated the antitumor response against breast cancer 4T1 cells in vitro. Furthermore, an immune memory was established in BALB/c mice after three-time preimmunization with the vacosome. After that, the immunized mice showed inhibited tumor growth and prolonged survival period (longer than 50 days). Overall, our results demonstrate that the vacosome can be a potential candidate for clinical translation as a cancer vaccine.

AB - Recently, there has been an increasing interest for utilizing the host immune system to fight against cancer. Moreover, cancer vaccines, which can stimulate the host immune system to respond to cancer in the long term, are being investigated as a promising approach to induce tumor-specific immunity. In this work, we prepared an effective cancer vaccine (denoted as "vacosome") by reconstructing the cancer cell membrane, monophosphoryl lipid A as a toll-like receptor 4 agonist, and egg phosphatidylcholine. The vacosome triggered and enhanced bone marrow dendritic cell maturation as well as stimulated the antitumor response against breast cancer 4T1 cells in vitro. Furthermore, an immune memory was established in BALB/c mice after three-time preimmunization with the vacosome. After that, the immunized mice showed inhibited tumor growth and prolonged survival period (longer than 50 days). Overall, our results demonstrate that the vacosome can be a potential candidate for clinical translation as a cancer vaccine.

UR - http://dx.doi.org/10.1021/acsami.0c15057

U2 - 10.1021/acsami.0c15057

DO - 10.1021/acsami.0c15057

M3 - Article

VL - 12

SP - 44554

EP - 44562

JO - ACS Applied Materials and Interfaces

JF - ACS Applied Materials and Interfaces

SN - 1944-8244

IS - 40

ER -

Recombination Monophosphoryl Lipid A-Derived Vacosome for the Development of Preventive Cancer Vaccines

Abstract

Access to Document

Other files and links

Fingerprint

InFLAMES: Innovation Ecosystem based on the Immune System

Cite this

Recombination Monophosphoryl Lipid A-Derived Vacosome for the Development of Preventive Cancer Vaccines

Abstract

Access to Document

Other files and links

Fingerprint

Projects

InFLAMES: Innovation Ecosystem based on the Immune System

Cite this